Remarkably, both ADAM10 G342E (score = −0,81) and ADAM15 N792S (score −1,1) missense pathogenic mutation were associated to low grade glioma, methylated MGMT promoter status and mutant IDH status, which correspond to a positive prognosis in glioma patients. Here, ADAM15 is linked to central nervous system cancer.